<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema - Mehta, H - 2018 | Cochrane Library</title> <meta content="Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema - Mehta, H - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema - Mehta, H - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011599.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema" name="citation_title"/> <meta content="Hemal Mehta" name="citation_author"/> <meta content="hm@cantab.net" name="citation_author_email"/> <meta content="Charles Hennings" name="citation_author"/> <meta content="Royal Free London NHS Foundation Trust" name="citation_author_institution"/> <meta content="Mark C Gillies" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Vuong Nguyen" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Anna Campain" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Samantha Fraser‐Bell" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD011599.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/04/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bevacizumab [*therapeutic use]; Dexamethasone [*therapeutic use]; Diabetic Retinopathy [*drug therapy, etiology, surgery]; Drug Therapy, Combination [methods]; Glucocorticoids [*therapeutic use]; Intraocular Pressure; Intravitreal Injections; Macula Lutea [drug effects]; Macular Edema [*drug therapy, etiology, surgery]; Randomized Controlled Trials as Topic; Ranibizumab [*therapeutic use]; Receptors, Vascular Endothelial Growth Factor [antagonists &amp; inhibitors]; Triamcinolone [*therapeutic use]; Vascular Endothelial Growth Factor A [*antagonists &amp; inhibitors]; Visual Acuity [drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011599.pub2&amp;doi=10.1002/14651858.CD011599.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xsb6SJyC";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011599\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011599\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011599.pub2",title:"Anti\\u2010vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema",firstPublishedDate:"Apr 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011599.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011599.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011599.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011599.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011599.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011599.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011599.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011599.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011599.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011599.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3226 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011599.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/appendices#CD011599-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/table_n/CD011599StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/table_n/CD011599StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#CD011599-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hemal Mehta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#CD011599-cr-0003">Charles Hennings</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#CD011599-cr-0004">Mark C Gillies</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#CD011599-cr-0005">Vuong Nguyen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#CD011599-cr-0006">Anna Campain</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#CD011599-cr-0007">Samantha Fraser‐Bell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information/en#CD011599-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 April 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011599.pub2">https://doi.org/10.1002/14651858.CD011599.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011599-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011599-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011599-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011599-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011599-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011599-abs-0001" lang="en"> <section id="CD011599-sec-0001"> <h3 class="title" id="CD011599-sec-0001">Background</h3> <p>The combination of steroid and anti‐vascular endothelial growth factor (VEGF) intravitreal therapeutic agents could potentially have synergistic effects for treating diabetic macular oedema (DMO). On the one hand, if combined treatment is more effective than monotherapy, there would be significant implications for improving patient outcomes. Conversely, if there is no added benefit of combination therapy, then people could be potentially exposed to unnecessary local or systemic side effects. </p> </section> <section id="CD011599-sec-0002"> <h3 class="title" id="CD011599-sec-0002">Objectives</h3> <p>To assess the effects of intravitreal agents that block vascular endothelial growth factor activity (anti‐VEGF agents) plus intravitreal steroids versus monotherapy with macular laser, intravitreal steroids or intravitreal anti‐VEGF agents for managing DMO. </p> </section> <section id="CD011599-sec-0003"> <h3 class="title" id="CD011599-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2018, Issue 1); Ovid MEDLINE; Ovid Embase; LILACS; the ISRCTN registry; ClinicalTrials.gov and the ICTRP. The date of the search was 21 February 2018. </p> </section> <section id="CD011599-sec-0004"> <h3 class="title" id="CD011599-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of intravitreal anti‐VEGF combined with intravitreal steroids versus intravitreal anti‐VEGF alone, intravitreal steroids alone or macular laser alone for managing DMO. We included people with DMO of all ages and both sexes. We also included trials where both eyes from one participant received different treatments. </p> </section> <section id="CD011599-sec-0005"> <h3 class="title" id="CD011599-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures recommended by Cochrane.Two authors independently reviewed all the titles and abstracts identified from the electronic and manual searches against the inclusion criteria. Our primary outcome was change in best corrected visual acuity (BCVA) between baseline and one year. Secondary outcomes included change in central macular thickness (CMT), economic data and quality of life. We considered adverse effects including intraocular inflammation, raised intraocular pressure (IOP) and development of cataract. </p> </section> <section id="CD011599-sec-0006"> <h3 class="title" id="CD011599-sec-0006">Main results</h3> <p>There were eight RCTs (703 participants, 817 eyes) that met our inclusion criteria with only three studies reporting outcomes at one year. The studies took place in Iran (3), USA (2), Brazil (1), Czech Republic (1) and South Korea (1). Seven studies used the unlicensed anti‐VEGF agent bevacizumab and one study used licensed ranibizumab. The study that used licensed ranibizumab had a unique design compared with the other studies in that included eyes had persisting DMO after anti‐VEGF monotherapy and received three monthly doses of ranibizumab prior to allocation. The anti‐VEGF agent was combined with intravitreal triamcinolone in six studies and with an intravitreal dexamethasone implant in two studies. The comparator group was anti‐VEGF alone in all studies; two studies had an additional steroid monotherapy arm, another study had an additional macular laser photocoagulation arm. Whilst we judged these studies to be at low risk of bias for most domains, at least one domain was at unclear risk in all studies. </p> <p>When comparing anti‐VEGF/steroid with anti‐VEGF monotherapy as primary therapy for DMO, we found no meaningful clinical difference in change in BCVA (mean difference (MD) −2.29 visual acuity (VA) letters, 95% confidence interval (CI) −6.03 to 1.45; 3 RCTs; 188 eyes; low‐certainty evidence) or change in CMT (MD 0.20 μm, 95% CI −37.14 to 37.53; 3 RCTs; 188 eyes; low‐certainty evidence) at one year. There was very low‐certainty evidence on intraocular inflammation from 8 studies, with one event in the anti‐VEGF/steroid group (313 eyes) and two events in the anti‐VEGF group (322 eyes). There was a greater risk of raised IOP (Peto odds ratio (OR) 8.13, 95% CI 4.67 to 14.16; 635 eyes; 8 RCTs; moderate‐certainty evidence) and development of cataract (Peto OR 7.49, 95% CI 2.87 to 19.60; 635 eyes; 8 RCTs; moderate‐certainty evidence) in eyes receiving anti‐VEGF/steroid compared with anti‐VEGF monotherapy. There was low‐certainty evidence from one study of an increased risk of systemic adverse events in the anti‐VEGF/steroid group compared with the anti‐VEGF alone group (Peto OR 1.32, 95% CI 0.61 to 2.86; 103 eyes). </p> <p>One study compared anti‐VEGF/steroid versus macular laser therapy. At one year investigators did not report a meaningful difference between the groups in change in BCVA (MD 4.00 VA letters 95% CI −2.70 to 10.70; 80 eyes; low‐certainty evidence) or change in CMT (MD −16.00 μm, 95% CI −68.93 to 36.93; 80 eyes; low‐certainty evidence). There was very low‐certainty evidence suggesting an increased risk of cataract in the anti‐VEGF/steroid group compared with the macular laser group (Peto OR 4.58, 95% 0.99 to 21.10, 100 eyes) and an increased risk of elevated IOP in the anti‐VEGF/steroid group compared with the macular laser group (Peto OR 9.49, 95% CI 2.86 to 31.51; 100 eyes). </p> <p>One study provided very low‐certainty evidence comparing anti‐VEGF/steroid versus steroid monotherapy at one year. There was no evidence of a meaningful difference in BCVA between treatments at one year (MD 0 VA letters, 95% CI ‐6.1 to 6.1, low‐certainty evidence). Likewise, there was no meaningful difference in the mean CMT at one year (MD ‐ 9 μm, 95% CI ‐39.87μm to 21.87μm between the anti‐VEGF/steroid group and the steroid group. There was very low‐certainty evidence on raised IOP at one year comparing the anti‐VEGF/steroid versus steroid groups (Peto OR 0.75, 95% CI 0.16 to 3.55). </p> <p>No included study reported impact of treatment on patients' quality of life or economic data. None of the studies reported any cases of endophthalmitis. </p> </section> <section id="CD011599-sec-0007"> <h3 class="title" id="CD011599-sec-0007">Authors' conclusions</h3> <p>Combination of intravitreal anti‐VEGF plus intravitreal steroids does not appear to offer additional visual benefit compared with monotherapy for DMO; at present the evidence for this is of low‐certainty. There was an increased rate of cataract development and raised intraocular pressure in eyes treated with anti‐VEGF plus steroid versus anti‐VEGF alone. Patients were exposed to potential side effects of both these agents without reported additional benefit. The majority of the evidence comes from studies of bevacizumab and triamcinolone used as primary therapy for DMO. There is limited evidence from studies using licensed intravitreal anti‐VEGF agents plus licensed intravitreal steroid implants with at least one year follow‐up. It is not known whether treatment response is different in eyes that are phakic and pseudophakic at baseline. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011599-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011599-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011599-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011599-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011599-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011599-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011599-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011599-abs-0004" lang="en"> <h3>Anti‐vascular endothelial growth factor (anti‐VEGF) plus intravitreal steroids for diabetic macular oedema </h3> <p><b>What is the aim of this review?</b><br/> The aim of this Cochrane Review was to find out whether injecting two drugs in combination (inhibitors of VEGF and steroids) into the vitreous jelly of eyes with macular oedema (swelling at the centre of the retina) due to diabetes works better than treatment with one drug alone. </p> <p><b>Key messages</b><br/> There is insufficient evidence to suggest that the two drugs in combination are better than treatment with one drug alone. </p> <p><b>What was studied in the review?</b><br/> Diabetic macular oedema is swelling at the back of the eye (retina) in people with diabetes. It is the most common cause of aquired visual loss in the mainly working‐age population. </p> <p>Both steroids and anti‐VEGF agents, injected into the vitreous jelly of the eye (intravitreal), improve vision and reduce the amount of fluid accumulating in the central retina. The drugs have different mechanisms of action and may work well in combination, with significant implications for improving patient outcomes. However, if there is no added benefit of combination therapy, then people could be potentially exposed to unnecessary side effects such as cataract, glaucoma, stroke and heart attack. </p> <p><b>What are the main results of the review?</b><br/> The Cochrane Review authors found eight relevant studies. Three studies were from Iran, two from USA and one each from Brazil, Czech Republic and South Korea. These studies compared an anti‐VEGF (in most studies an unlicensed version called bevacizumab) plus intravitreal steroid agents versus anti‐VEGF alone, an intravitreal steroid alone or macular laser alone. </p> <p>We found insufficient evidence to suggest that the two drugs classes in combination are better than treatment with one drug class alone as the initial treatment for diabetic macula oedema. Moreover, there was a greater risk of raised intraocular pressure and cataract in people receiving anti‐VEGF plus steroids compared with anti‐VEGF alone. </p> <p><b>How up‐to‐date is this review?</b><br/> Cochrane Review authors searched for studies that had been published up to 21 February 2018. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011599-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011599-sec-0090">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011599-sec-0159">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011599-sec-0090"></div> <h3 class="title" id="CD011599-sec-0091">Implications for practice</h3> <section id="CD011599-sec-0091"> <p>Combination of intravitreal anti‐VEGF plus intravitreal steroids does not appear to offer additional visual benefit compared with monotherapy for DMO; at present the evidence for this is of low‐certainty. There was an increased rate of cataract development and raised intraocular pressure in eyes treated with anti‐VEGF plus steroid versus anti‐VEGF alone. Patients were exposed to potential side effects of both these agents without reported additional benefit. The majority of the evidence comes from studies of bevacizumab and triamcinolone used as primary therapy for DMO. </p> </section> <h3 class="title" id="CD011599-sec-0092">Implications for research</h3> <section id="CD011599-sec-0092"> <p>Agreed standardised ocular (e.g. intraocular pressure rise) and systemic (e.g. cardiovascular events) safety outcome measures would allow easier comparison of results. Quality of life and cost benefit indices should also be reported in future clinical trials. Evaluating differences in the relative effect of inhibitors of VEGF and intravitreal steroids on proliferative diabetic retinopathy and foveal threatening hard exudates would help clinicians understand whether these agents can be used in combination to target different aspects of diabetic retinopathy. There is limited evidence from studies using licensed intravitreal anti‐VEGF agents plus licensed intravitreal steroid implants with at least one year follow‐up. It is not known whether treatment response is different in eyes that are phakic and pseudophakic at baseline. The role of combined inhibitors of VEGF and steroid implants for DMO specifically at the time of cataract surgery has not been addressed in the included randomised clinical trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011599-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011599-sec-0022"></div> <div class="table" id="CD011599-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Settings</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal anti‐VEGF plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: intravitreal anti‐VEGF </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of eyes<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF alone</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity gain at 1 year ranged from 4.9 to 10.5 letters in the anti‐VEGF alone groups </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read was on average 2.29 fewer in the anti‐VEGF/steroid group (95% CI −6.03 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> <p>(3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in central macular thickness at 1 year ranged from −30 μm to −179 μm in the anti‐VEGF alone groups </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in central macular thickness was on average 0.20 μm greater in the anti‐VEGF/steroid groups (95% CI −37.14 to 37.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> <p>(3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> <p>(0 to 30 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.53 (0.05 to 5.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> <p>(8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 3 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> <p>(9 to 56 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.49 (2.87 to 19.60)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> <p>(8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NB: significant cataract progression may occur in the second year of intravitreal steroid use. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Raised intraocular pressure at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> <p>(27 to 79 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 8.13 (4.67 to 14.16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> <p>(8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant needed glaucoma surgery in the anti‐VEGF/steroid group.<b>This outcome occurred only in 1 study</b>. The threshold for glaucoma drainage surgery was not specified. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>468 per 1000</p> <p>(289 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peto OR 1.32</p> <p>(95% CI 0.61 to 2.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br/> <b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>MD</b> : mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level because of imprecision.<br/> <sup>b</sup>Downgraded one level because of risk of bias, and two levels for imprecision as there were very few events. </p> <p><sup>c</sup>Downgraded one level because of risk of bias </p> <p><sup>d</sup>Downgraded two levels for imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011599-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Setting</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal bevacizumab plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: macular laser </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of eyes<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Macular laser</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity gain at 1 year was 1 letter with a standard deviation of 17 letters in the laser comparator group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read was 4.00 more in the anti‐VEGF/steroid group (95% CI −2.70 to 10.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gain or loss of 10 or more letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in central macular thickness at 1 year was an increase of 6 μm with a standard deviation of 36 microns in the laser comparator group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in central macular thickness was on average 16 μm greater in the anti‐VEGF/steroid group (95% CI −68.93 to 36.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> <p>(20 to 301 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 4.58 (0.99 to 21.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Raised Intraocular Pressure at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> <p>(3 to 31 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 9.49 (2.86 to 31.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was 1 participant who needed glaucoma drainage surgery in the anti‐VEGF/steroid group. Threshold for glaucoma drainage surgery not specified in the included study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br/> <b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>MD</b> : mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level due to imprecision. </p> <p><sup>b</sup>Downgraded one level because of risk of bias and by two levels due to imprecision (only 1 event in the comparator group). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011599-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus intravitreal steroid for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Intravitreal bevacizumab plus intravitreal steroid compared with intravitreal steroid for diabetic macular oedema </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Setting</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal bevacizumab plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: intravitreal steroid (IVS) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of eyes<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainity of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IVS</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity at 1 year was 24.5 letters in the IVS comparator group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read was on average 0 letters higher (i.e same) in the anti‐VEGF/steroid group (95% CI ‐6.1 to 6.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported for change in visual acuity so difference in visual acuity at 1 year reported </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gain or loss of 10 or more letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean central macular thickness was 249 μm in the IVS comparator group at 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean central macular thickness was 9 μm less in the anti‐VEGF/steroid group (‐39.87μm less to 21.87μm more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported for change so difference in final value reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Raised intraocular pressure at 1 year at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> <p>(19 to 301 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.75 (0.16 to 3.55)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br/> <b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>MD</b> : mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level for imprecision. </p> <p><sup>b</sup>Downgraded one level because of risk of bias and by two levels for imprecision (very few events). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011599-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011599-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011599-sec-0117">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011599-sec-0023"></div> <section id="CD011599-sec-0024"> <h3 class="title" id="CD011599-sec-0024">Description of the condition</h3> <p>The worldwide prevalence of diabetes mellitus was estimated at 366 million in 2011, with projections that by 2030 the prevalence will reach 552 million people (<a href="./references#CD011599-bbs2-0036" title="International Diabetes Federation. Diabetes Atlas. 5th Edition. Brussels: International Diabetes Federation, 2011. ">International Diabetes Federation 2011</a>). Diabetic macular oedema (DMO) is the most common cause of acquired visual loss in this population, affecting approximately 6.8% of all people with diabetes (<a href="./references#CD011599-bbs2-0019" title="AntonettiDA , KleinR , GardnerTW . Diabetic retinopathy. New England Journal of Medicine2012;366(13):1227‐39. ">Antonetti 2012</a>; <a href="./references#CD011599-bbs2-0026" title="BunceC , WormaldR . Causes of blind certifications in England and Wales: April 1999‐March 2000. Eye2008;22(7):905‐11. ">Bunce 2008</a>; <a href="./references#CD011599-bbs2-0041" title="MossSE , KleinR , KleinBE . The 14‐year incidence of visual loss in a diabetic population. Ophthalmology1998;105(6):998‐1003. ">Moss 1998</a>; <a href="./references#CD011599-bbs2-0054" title="YauJW , RogersSL , KawasakiR , LamoureuxEL , KowalskiJW , BekT , et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012;35(3):556‐64. ">Yau 2012</a>). </p> </section> <section id="CD011599-sec-0025"> <h3 class="title" id="CD011599-sec-0025">Description of the intervention</h3> <p>Systemic therapies aim to prevent or reduce DMO by targeting key modifiable risk factors. However, intensive control of glucose and blood pressure in clinical trials has achieved only limited success in preventing diabetic retinopathy (<a href="./references#CD011599-bbs2-0039" title="LiewG , GilliesMC , WangJJ . Fenofibrate and diabetic retinopathy. Lancet2008;371(9614):721. ">Liew 2008</a>). There may also be a role for modification of the renin‐angiotensin system and for lipid‐lowering agents in the management of DMO (<a href="./references#CD011599-bbs2-0038" title="KiireCA , PortaM , ChongV . Medical management for the prevention and treatment of diabetic macular edema. Survey of Ophthalmology2013;58(5):459‐65. ">Kiire 2013</a>). Fenofibrate may have a beneficial effect, although its mechanism of action appears to be independent of serum lipid concentration (<a href="./references#CD011599-bbs2-0037" title="KeechAC , MitchellP , SummanenPA , O'DayJ , DavisTM , MoffittMS , et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet2007;370(9600):1687‐97. ">Keech 2007</a>; <a href="./references#CD011599-bbs2-0039" title="LiewG , GilliesMC , WangJJ . Fenofibrate and diabetic retinopathy. Lancet2008;371(9614):721. ">Liew 2008</a>; <a href="./references#CD011599-bbs2-0043" title="ScheenAJ , VanGaalLF . Accord‐lipid and accord‐eye: towards a new positioning of fenofibrate in the management of type 2 diabetes. Revue Medicale de Liege2010;65(9):533‐9. ">Scheen 2010</a>). </p> <p>Up until the introduction of intravitreal pharmacotherapies, the standard of care for DMO was focal or grid laser photocoagulation. The Early Treatment Diabetic Retinopathy Study (ETDRS), which was undertaken in the 1980s, showed benefit of laser for DMO compared with no intervention (<a href="./references#CD011599-bbs2-0029" title="Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology1991;98(5 Suppl):807‐22. ">ETDRS 1991</a>). In this trial the three‐year risk of moderate visual loss, defined as a loss of 15 letters or 3 lines of LogMAR visual acuity, decreased by 50% in laser‐treated eyes. Nonetheless, in most people with DMO, laser does not improve vision. Thus there was a major unmet need in terms of better treatments for DMO. </p> <p>A systematic review found little evidence to support vitrectomy as an intervention for DMO in the absence of epiretinal membrane or vitreomacular traction (<a href="./references#CD011599-bbs2-0046" title="SimunovicMP , HunyorAP , HoIV . Vitrectomy for diabetic macular edema: a systematic review and meta‐analysis. Canadian Journal of Ophthalmology2014;49(2):188‐95. ">Simunovic 2014</a>). </p> <p>Some authors have proposed intravitreal steroid formulations such as triamcinolone acetate injections (IVTA), slow‐release dexamethasone implants and sustained‐release fluocinolone acetonide implants to treat clinically significant DMO (<a href="./references#CD011599-bbs2-0025" title="BoyerDS , FaberD , GuptaS , PatelSS , TabandehH , LiXY , et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina2011;31(5):915‐23. ">Boyer 2011</a>; <a href="./references#CD011599-bbs2-0027" title="CampochiaroPA , BrownDM , PearsonA , ChenS , BoyerD , Ruiz‐MorenoJ , et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology2012;119(10):2125‐32. ">Campochiaro 2012</a>; <a href="./references#CD011599-bbs2-0032" title="GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five‐year results of a randomized trial with open‐label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182–7. ">Gillies 2009</a>). A Cochrane Review of intravitreal steroids in DMO concluded that steroids placed inside the eye by either intravitreal injection or surgical implantation may improve visual outcomes in eyes with persistent or refractory DMO; however, eyes treated with these formulations also frequently experience elevation of intraocular pressure and cataract progression (<a href="./references#CD011599-bbs2-0034" title="GroverD , LiTJ , ChongCCW . Intravitreal steroids for macular edema in diabetes. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005656.pub2] ">Grover 2008</a>). </p> <p>A Cochrane Review of antiangiogenic therapy in DMO identified strong evidence of a clinical benefit in maintaining and improving vision using anti‐vascular endothelial growth factor (anti‐VEGF) drugs versus laser photocoagulation (<a href="./references#CD011599-bbs2-0048" title="VirgiliG , ParravanoM , MenchiniF , EvansJR . Anti‐vascular endothelial growth factor for diabetic macular oedema. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD007419.pub4] ">Virgili 2014</a>). The systematic review reported that further data are needed to assess effectiveness under real‐world monitoring and treatment conditions as well as safety (particularly regarding cardiovascular risk) in high‐risk populations excluded from clinical trials (<a href="./references#CD011599-bbs2-0048" title="VirgiliG , ParravanoM , MenchiniF , EvansJR . Anti‐vascular endothelial growth factor for diabetic macular oedema. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD007419.pub4] ">Virgili 2014</a>; <a href="./references#CD011599-bbs2-0049" title="VirgiliG , ParravanoM , MenchiniF , EvansJR , GordonI , LucenteforteE . Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis. Cochrane Database of Systematic Reviews2017, Issue 6. [DOI: 10.1002/14651858.CD007419.pub5] ">Virgili 2017</a>; <a href="./references#CD011599-bbs2-0052" title="WongLJ , DesaiRU , JainA , FelicianoD , MoshfeghiDM , SanisloSR , et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina2008;28(8):1151‐8. ">Wong 2008</a>). </p> <p>Combinations of the above intravitreal anti‐VEGF and steroid formulations are the subject of this review. </p> </section> <section id="CD011599-sec-0026"> <h3 class="title" id="CD011599-sec-0026">How the intervention might work</h3> <p>Diabetic macular oedema is multifactorial, with significantly elevated levels of VEGF, interleukin‐6, and intercellular adhesion molecule‐1 in people with extensive DMO leakage versus those with minimal leakage (<a href="./references#CD011599-bbs2-0030" title="FunatsuH , YamashitaH , IkedaT , MimuraT , EguchiS , HoriS . Vitreous levels of interleukin‐6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology2003;110(9):1690‐6. ">Funatsu 2003</a>; <a href="./references#CD011599-bbs2-0031" title="FunatsuH , YamashitaH , SakataK , NomaH , MimuraT , SuzukiM , et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology2005;112(5):806‐16. ">Funatsu 2005</a>). Post hoc analyses of head‐to‐head clinical trial data have reported differences between the effects of intravitreal anti‐VEGF and intravitreal steroids on surrogate endpoints of hard exudate resolution and vessel calibre diameter, suggesting different mechanisms of action in resolving DMO (<a href="./references#CD011599-bbs2-0040" title="MehtaH , Fraser‐BellS , YeungA , CampainA , LimLL , QuinGJ , et al. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. British Journal of Ophthalmology2016;100(7):1000‐4. ">Mehta 2016</a>; <a href="./references#CD011599-bbs2-0051" title="WickremasingheSS , Fraser‐BellS , AlessandrelloE , MehtaH , GilliesMC , LimLL . Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema. British Journal of Ophthalmology2017;101(10):1329‐33. ">Wickremasinghe 2017</a>). Steroid therapy has anti‐inflammatory, anti‐permeability and angiostatic effects in treating DMO (<a href="./references#CD011599-bbs2-0050" title="WangK , WangY , GaoL , LiX , LiM , GuoJ . Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin‐induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule‐1 expression. Biological and Pharmaceutical Bulletin2008;31(8):1541‐6. ">Wang 2008</a>). Anti‐VEGF agents, by inhibition of VEGF angiogenic activity on endothelial tight junctions, reduce retinal vascular permeability (<a href="./references#CD011599-bbs2-0017" title="AielloLP . Angiogenic pathways in diabetic retinopathy. New England Journal of Medicine2005;353(8):839‐41. ">Aiello 2005</a>). The combination of steroid and anti‐VEGF intravitreal therapeutic agents could potentially have synergistic effects for treating DMO (<a href="./references#CD011599-bbs2-0018" title="AmoakuWM , SakerS , StewartEA . A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye2015;29(9):1115‐30. ">Amoaku 2015</a>). </p> </section> <section id="CD011599-sec-0027"> <h3 class="title" id="CD011599-sec-0027">Why it is important to do this review</h3> <p>This systematic review will assess the effects of combining intravitreal anti‐VEGF and steroid agents for managing DMO. We will assess the evidence base as to whether combining the intravitreal therapies has any advantage over monotherapy with macular laser, intravitreal steroids or intravitreal anti‐VEGF agents in terms of functional (visual acuity) and anatomical (central macular thickness) outcomes. We will also address how the safety profile of the combined treatment compares to monotherapy. On the one hand, if combined treatment is more effective than monotherapy, there would be significant implications for improving patient outcomes worldwide. On the other hand, if there is no added benefit of combination therapy, then people could be potentially exposed to unnecessary local or systemic side effects. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011599-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011599-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011599-sec-0122">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011599-sec-0028"></div> <p>To assess the effects of intravitreal agents that block vascular endothelial growth factor activity (anti‐VEGF agents) plus intravitreal steroids versus monotherapy with macular laser, intravitreal steroids or intravitreal anti‐VEGF agents for managing diabetic macular oedema. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011599-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011599-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011599-sec-0123">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011599-sec-0029"></div> <section id="CD011599-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011599-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials (RCTs).</p> </section> <section id="CD011599-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included people with diabetic macular oedema (DMO) of all ages and both sexes as diagnosed in the included studies. We included trials where the eyes from one participant had received different treatments. </p> </section> <section id="CD011599-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included RCTs comparing intravitreal anti‐VEGF plus intravitreal steroids versus intravitreal anti‐VEGF alone, intravitreal steroids alone or macular laser alone for managing DMO. </p> </section> <section id="CD011599-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We excluded studies with follow‐up of less than six months.</p> <section id="CD011599-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD011599-sec-0036"> <h6 class="title">Visual acuity</h6> <p>The primary outcome for this review was mean change in best corrected visual acuity (BCVA) from baseline in the treated eye. We also assessed the proportion of eyes with at least 10 ETDRS letters' (equivalent to 2 ETDRS lines') change (<a href="./references#CD011599-bbs2-0021" title="BaileyIL , LovieJE . New design principles for visual acuity letter charts. American Journal of Optometry and Physiological Optics1976;53(11):740‐5. ">Bailey 1976</a>). Our primary analysis was at one year after randomisation. </p> </section> </section> <section id="CD011599-sec-0037"> <h5 class="title">Secondary outcomes</h5> <section id="CD011599-sec-0038"> <h6 class="title">Visual acuity</h6> <p>We also assessed the above visual acuity outcomes at six months and at two years.</p> </section> <section id="CD011599-sec-0039"> <h6 class="title">Anatomical outcomes</h6> <p>Mean change in central macular thickness (μm) as measured by optical coherence tomography (OCT) at six months, one year and two years. </p> </section> <section id="CD011599-sec-0040"> <h6 class="title">Safety</h6> <p>We reported the frequency and severity of ocular or systemic adverse outcomes in the studies. In particular, we identified the following ocular adverse events reported in included randomised clinical trials: endophthalmitis, retinal tears or detachment, intraocular inflammation, development of cataract, raised intraocular pressure and need for glaucoma drainage surgery. We also recorded systemic side effects including thromboembolic events (as defined by the Antiplatelet Trialists' Collaboration), non‐ocular haemorrhage and hypertension (<a href="./references#CD011599-bbs2-0020" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy‐I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308(6921):81‐106. ">APTC 1994</a>; <a href="./references#CD011599-bbs2-0024" title="BoyerDS , HeierJS , BrownDM , FrancomSF , IanchulevT , RubioRG . A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age‐related macular degeneration. Ophthalmology2009;116(9):1731‐9. ">Boyer 2009</a>). </p> </section> <section id="CD011599-sec-0041"> <h6 class="title">Economic data</h6> <p>We reported any cost benefit data in the included studies.</p> </section> <section id="CD011599-sec-0042"> <h6 class="title">Quality of life data</h6> <p>We reported any quality of life data in the included studies.</p> </section> </section> </section> </section> <section id="CD011599-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011599-sec-0044"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following databases for RCTs and controlled clinical trials. There were no language or publication year restrictions. The date of the search was 21 February 2018. </p> <p> <ul id="CD011599-list-0001"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 1) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 21 February 2018) (<a href="./appendices#CD011599-sec-0096">Appendix 1</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to 21 February 2018) (<a href="./appendices#CD011599-sec-0097">Appendix 2</a>); </p> </li> <li> <p>Embase Ovid (1980 to 21 February 2018) (<a href="./appendices#CD011599-sec-0098">Appendix 3</a>); </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database (1982 to 21 February 2018) (<a href="./appendices#CD011599-sec-0099">Appendix 4</a>); </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 21 February 2018) (<a href="./appendices#CD011599-sec-0100">Appendix 5</a>); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 21 February 2018) (<a href="./appendices#CD011599-sec-0101">Appendix 6</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 21 February 2018) (<a href="./appendices#CD011599-sec-0102">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD011599-sec-0045"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of the included trials to try to identify other relevant trials. </p> </section> </section> <section id="CD011599-sec-0046"> <h3 class="title" id="CD011599-sec-0046">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> <section id="CD011599-sec-0047"> <h4 class="title">Selection of studies</h4> <p>Two authors independently reviewed all the titles and abstracts identified from the electronic and manual searches against the inclusion criteria. We obtained full‐text copies of all potentially or definitely relevant articles. We contacted trial investigators for further information if required. We resolved discrepancies between authors as to whether or not studies met inclusion criteria by discussion. We documented the excluded studies and reasons for exclusion in the <a href="./references#CD011599-sec-0115" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD011599-sec-0048"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following participant and trial characteristics and reported them in a table format (<a href="./appendices#CD011599-sec-0103">Appendix 8</a>). </p> <p> <ol id="CD011599-list-0002"> <li> <p>Participant characteristics (age, sex, glycated haemoglobin (HbA1c), diagnostic criteria used for DMO, baseline visual acuity, OCT‐determined central macular thickness, and fluorescein angiography assessment of macular ischaemia). </p> </li> <li> <p>Intervention (agent, dose, timing of first dose in relation to diagnosis, delivery route, frequency, treatment length). </p> </li> <li> <p>Methodology (group size, randomisation, masking).</p> </li> <li> <p>Results (visual acuity, central macular thickness, and adverse events).</p> </li> <li> <p>Additional data (economic data, quality‐of‐life data).</p> </li> <li> <p>Treatment compliance and losses to follow‐up.</p> </li> </ol> </p> <p>We contacted trial investigators for key unpublished information that was missing from the reports of the included studies. Two review authors independently extracted the data and recorded it on paper data extraction forms developed by Cochrane Eyes and Vision. We resolved discrepancies by discussion. One review author entered all data into Review Manager 5 (RevMan 5) (<a href="./references#CD011599-bbs2-0042" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and a second author checked that the data entered were correct. </p> </section> <section id="CD011599-sec-0049"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias of the selected trials according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011599-bbs2-0035" title="HigginsJP , AltmanDG , Sterne JACeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We considered the following main criteria. </p> <p>• Selection bias: random sequence generation, allocation concealment.<br/> • Performance bias: masking of participants, researchers and outcome assessors.<br/> • Attrition bias: loss to follow‐up, rates of compliance.<br/> • Reporting bias: selective outcome reporting. </p> <p>We reported each parameter as being at high risk of bias, low risk of bias, or unclear risk of bias. We resolved discrepancies between the authors by discussion. We contacted study authors to clarify details for any studies at unclear risk of bias. If there was no response from the authors, we classified the trial based on available information. </p> <p>For multi‐arm studies, we analysed multiple intervention groups in an appropriate way that avoided arbitrary omission of relevant groups and prevented double counting of participants. </p> </section> <section id="CD011599-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>We measured treatment effects according to the data types described in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011599-bbs2-0028" title="DeeksJJ , HigginsJP , Altman DGeditor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <section id="CD011599-sec-0051"> <h5 class="title">Dichotomous data</h5> <p>Variables in this group include the primary outcome and the proportion of participants experiencing an adverse event during follow‐up. We reported dichotomous variables as risk ratios (RRs) with 95% confidence intervals (CIs). </p> </section> <section id="CD011599-sec-0052"> <h5 class="title">Continuous data</h5> <p>These variables include mean change in visual acuity and central macular thickness. We reported continuous variables as mean difference with 95% CI (if normally distributed) or median and interquartile range (if not normally distributed). </p> </section> </section> <section id="CD011599-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis for efficacy of treatment and ocular safety was the eye for which the data had been reported on. </p> <p>Trials could randomise one or both eyes to the intervention or comparator. If people were randomly allocated to treatment but the trial included only one eye per person, then there was no unit of analysis issue. In these cases, we documented how investigators selected the included eye. If people were randomly allocated to treatment but trials included and reported on both eyes, we adjusted for within‐person correlation by analysing as 'clustered data'. If the study was a within‐person study, i.e. one eye was randomly allocated to intervention and the other eye received the comparator, then we analysed the results as paired data. If required, we contacted the trial investigators for further information to carry out these analyses. </p> <p>The unit of analysis for systemic safety, economic and quality of life measures was the individual, with inferences as to effect of a treatment at the person level based on unpaired data only. </p> </section> <section id="CD011599-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to identify key unpublished information that was missing from reports of included studies by contacting study authors. If the authors did not respond within four weeks or were not able to provide additional data, we conducted a primary analysis based on participants with complete data (available case analysis). We made a judgement as to the risk of bias based on the amount and distribution of missing data in the study arms. Missing standard deviations were imputed using the largest reported standard deviation from the remaining included studies. We conducted a sensitivity analysis excluding studies with missing standard deviations. </p> </section> <section id="CD011599-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered sources of heterogeneity related to study design (such as paired studies versus studies including only one eye of each participant) and baseline characteristics. We used I² value to determine the proportion of the variation that reflects variation in true effects (<a href="./references#CD011599-bbs2-0035" title="HigginsJP , AltmanDG , Sterne JACeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We considered I² values of greater than 50% to represent substantial heterogeneity not attributed to random error. </p> </section> <section id="CD011599-sec-0056"> <h4 class="title">Data synthesis</h4> <p>If there was no substantial clinical or statistical heterogeneity between the trials, we combined the results in a meta‐analysis using a random‐effects model. We used a fixed‐effect model if there were three or fewer trials. We also used this model if there were forest plots with few events, in which case we expressed effect measures as Peto odds ratios (ORs). In case of substantial clinical or statistical heterogeneity, we did not combine study results but presented a narrative or tabulated summary. An exception where pooling of data would still occur even in the presence of substantial statistical heterogeneity would be where examination of the forest plot indicated the individual trial results were all consistent in their direction of effect (i.e. the risk ratio and confidence intervals largely fall on one side of the line of null effect). </p> </section> <section id="CD011599-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted a sensitivity analyses on the primary review outcome to determine the impact of excluding studies with missing data such as standard deviations, lower methodological quality (defined as high risk of bias in one or more domains),. </p> <section id="CD011599-sec-0058"> <h5 class="title">Summary of findings table</h5> <p>A 'Summary of findings' table provides key information concerning the certainty of evidence, the magnitude of effect of the interventions examined, and the sum of available data on all specified review primary and secondary outcomes for a given comparison. Two review authors independently used the GRADE approach to assess the certainty of the evidence for each outcome as described in the standard methods of Chapters 11 and 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011599-bbs2-0044" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>; <a href="./references#CD011599-bbs2-0045" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011b</a>). We resolved discrepancies by discussion. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011599-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011599-sec-0059"></div> <section id="CD011599-sec-0060"> <h3 class="title">Description of studies</h3> <p>There was not sufficient data at participant level in the included studies to assess for clustered data in trials with a paired design. We considered paired versus studies with only one eye per participant as a source of heterogeneity but all included studies reporting the primary outcome at one year had the possibility of both eyes being enrolled. </p> <section id="CD011599-sec-0061"> <h4 class="title">Results of the search</h4> <p>The electronic searches yielded a total of 1057 records (<a href="#CD011599-fig-0001">Figure 1</a>). After removing 282 duplicates, the Cochrane Information Specialist screened the remaining 775 records and removed 450 references that were not relevant to the review. We made additional searches of the ongoing trials registers and identified a further two studies for assessment. We screened 327 references and obtained 20 full‐text reports for further assessment. We included 13 reports of eight studies (see <a href="./references#CD011599-sec-0114" title="">Characteristics of included studies</a> ), and excluded five studies (see <a href="./references#CD011599-sec-0115" title="">Characteristics of excluded studies</a>). We identified two ongoing studies (<a href="./references#CD011599-bbs2-0014" title="NCT03126786 . Suprachoroidal CLS‐TA with intravitreal aflibercept versus aflibercept alone in subject with diabetic macular edema (TYBEE). clinicaltrials.gov/show/NCT03126786 (first posted 24 April 2017). ">NCT03126786</a>; <a href="./references#CD011599-bbs2-0015" title="UMIN000021630 . Anti‐VEGF and steroid combination therapy for diabetic macular edema. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000021630 (date of registration 27 March 2016). ">UMIN000021630</a>) and will assess these for potential inclusion in the review when data becomes available. </p> <div class="figure" id="CD011599-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011599-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011599-sec-0062"> <h4 class="title">Included studies</h4> <p>We included 13 publications of eight RCTs in this review (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>; <a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a>; <a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a>; <a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a>; <a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a>; <a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a>; <a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a>; <a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a>). Most studies used the unlicensed anti‐VEGF agent bevacizumab and one study used ranibizumab (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>). Regarding the use of intravitreal steroid, six studies used intravitreal triamcinolone, whilst two studies used the intravitreal dexamethasone implant (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>; <a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a>). Two of the RCTs (<a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a>; <a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a>) had used selected population subgroups referencing participants from previous trials (<a href="./references#CD011599-bbs2-0016" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ">Ahmadieh 2008</a>; <a href="./references#CD011599-bbs2-0047" title="SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. ">Soheilian 2009</a>;<a href="./references#CD011599-bbs2-0053" title="YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Yaseri 2014</a>). One study (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>) had a unique design compared with the other studies in that included eyes had persisting DMO after anti‐VEGF monotherapy and received three monthly doses of ranibizumab prior to allocation.Three studies were from Iran and one each from the Republic of Korea, the USA and the Czech Republic. We have documented the number of participants and eyes in each study and a summary of the characteristics of the study populations and settings, interventions, comparators and funding sources in the <a href="./references#CD011599-sec-0114" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD011599-sec-0063"> <h4 class="title">Excluded studies</h4> <p>We excluded five studies because of insufficient length of follow‐up (<a href="./references#CD011599-bbs2-0009" title="FaghihiH , RoohipoorR , MohammadiSF , Hojat‐JalaliK , MirshahiA , LashayA , et al. Intravitreal bevacizumab versus combined bevacizumab‐triamcinolone versus macular laser photocoagulation in diabetic macular edema. European Journal of Ophthalmology2008;18(6):941‐8. ">Faghihi 2008</a>; <a href="./references#CD011599-bbs2-0010" title="ShethS , RushR , NatarajanS , GilliesM . Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Clinical and Experimental Ophthalmology2011;39(7):673‐81. ">Sheth 2011</a>; <a href="./references#CD011599-bbs2-0011" title="SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187‐95. ">Soheilian 2007</a>; <a href="./references#CD011599-bbs2-0012" title="WangYS , LiX , WangHY , ZhangZF , LiMH , SuXN . Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Chinese Medical Journal2011;124(3):352‐8. ">Wang 2011</a>; <a href="./references#CD011599-bbs2-0013" title="YuS Y , NamD H , LeeD Y . Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol2018;256:39‐47. ">Yu 2018</a>). See the <a href="./references#CD011599-sec-0115" title="">Characteristics of excluded studies</a> table for further information. </p> </section> </section> <section id="CD011599-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>All included studies were at unclear risk of bias in one or more domains (see <a href="#CD011599-fig-0002">Figure 2</a>; <a href="#CD011599-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD011599-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011599-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011599-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011599-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011599-sec-0065"> <h4 class="title">Allocation</h4> <p>We judged the risk of selection bias to be low in most studies. In <a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> and <a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> the methods of generating and concealing the allocation sequence were not reported in enough detail to make a judgement. </p> </section> <section id="CD011599-sec-0066"> <h4 class="title">Blinding</h4> <p>In five studies, authors stated that participants were masked to treatment allocation (<a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a>; <a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a>; <a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a>; <a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a>; <a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a>), but only two trials also masked the investigators delivering treatment (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>; <a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017)</a>. Five trials specified that masked investigators assessed outcome measures (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>; <a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a>; <a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a>; <a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a>; <a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a>), but this was not reported in the other three studies (<a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a>; <a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a>; <a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a>). </p> </section> <section id="CD011599-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies were judged to be at low risk of attrition bias as follow‐up was high (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>; <a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a>; <a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a>). <a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> was judged to be at high risk of attrition bias because of unequal loss to follow‐up in the groups, possibly attributable to adverse events. For the other studies, follow‐up was not reported in enough detail to make a judgement. </p> </section> <section id="CD011599-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Visual acuity and central macular thickness (CMT) data were in general well recorded. Authors did not always include safety data, particularly relating to systemic safety. The included RCTs were not powered to identify small increases in ocular or systemic harm. </p> </section> <section id="CD011599-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>Most studies enrolled a small proportion of participants with both eyes affected. Both eyes being eligible for allocation in a single individual poses the theoretical potential to influence outcomes in the fellow eye via systemic absorption. </p> </section> </section> <section id="CD011599-sec-0070"> <h3 class="title" id="CD011599-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD011599-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</a>; <a href="./full#CD011599-tbl-0002"><b>Summary of findings 2</b> Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema</a>; <a href="./full#CD011599-tbl-0003"><b>Summary of findings 3</b> Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus intravitreal steroid for diabetic macular oedema</a> </p> <p>See: <a href="./full#CD011599-tbl-0001">summary of findings Table for the main comparison</a> (anti‐VEGF/steroid versus anti‐VEGF alone); <a href="./full#CD011599-tbl-0002">summary of findings Table 2</a> (anti‐VEGF/steroid versus macular laser); <a href="./full#CD011599-tbl-0003">summary of findings Table 3</a> (anti‐VEGF/steroid versus steroid). </p> <p>We could not perform meta‐analyses when comparing anti‐VEGF/steroid versus steroid monotherapy or macular laser monotherapy due to there only being one included studies reporting each comparison at 12 month. There was no evidence that BCVA and CMT data were skewed in included studies. There were no reported cases of endophthalmitis in included studies. Systemic side‐effects were not fully reported. We did not identify any relevant studies reporting cost benefit or quality of life outcomes. Therefore, we were unable to comment on these secondary outcomes. </p> <section id="CD011599-sec-0071"> <h4 class="title">Intravitreal anti‐VEGF plus steroid versus anti‐VEGF alone</h4> <section id="CD011599-sec-0072"> <h5 class="title">Visual outcome</h5> <p>Eyes that received intravitreal anti‐VEGF plus steroid could read fewer average letters at one year compared with those receiving anti‐VEGF alone. The difference was small, and the confidence intervals (CIs) corresponded to either fewer or more letters being read (mean difference (MD) −2.29 visual acuity (VA) letters, 95% confidence interval (CI) −6.03 to 1.45, P = 0.23; 188 eyes; 3 studies, <a href="#CD011599-fig-0004">Figure 4</a>). The same pattern was apparent at six months (MD ‐0.88 VA letters, 95% CI ‐2.56 to 0.80; 618 eyes; 8 studies, <a href="./references#CD011599-fig-0007" title="">Analysis 1.1</a>) and at two years (MD −0.50 VA letters, 95% CI −8.42 to 7.42; 75 eyes, 1 study, <a href="./references#CD011599-fig-0009" title="">Analysis 1.3</a>). One study (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>) reported 10 letter gain and loss of vision at 6 months. An improvement of 10 letters or more was observed in 14 of the 63 eyes (22%) in the anti‐VEGF plus steroid group and 9 of the 64 eyes (14%) in the anti‐VEGF group (adjusted difference, 6%; 95 CI −6% to 18%; P = 0.34). In the anti‐VEGF plus steroid group, 8 eyes (13%) lost 10 letters or more compared with 4 (6%) for anti‐VEGF group (adjusted difference, 7%; 95% CI, −1% to 16%; P = 0.09); We judged the certainty of the visual acuity evidence described above to be low, downgrading for risk of bias in the included trials and imprecision (confidence intervals include both no effect and clinically important differences). </p> <div class="figure" id="CD011599-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.2 Mean change in visual acuity at 1 year [VA letters]." data-id="CD011599-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.2 Mean change in visual acuity at 1 year [VA letters]. </p> </div> </div> </div> </section> <section id="CD011599-sec-0073"> <h5 class="title">Central macular thickness</h5> <p>Eyes that received intravitreal anti‐VEGF plus steroid had reduced CMT at one year compared with those receiving anti‐VEGF alone. The difference was negligible, and the confidence intervals corresponded to either increased or decreased CMT (MD −0.20 μm, 95% CI −37.14 to 37.53, P = 0.99; 188 eyes; 3 studies; <a href="#CD011599-fig-0005">Figure 5</a>). There were similar results at six months (MD ‐19.73 μm, 95% CI ‐40.47 to 1.01; 617 eyes; 8 studies, <a href="./references#CD011599-fig-0010" title="">Analysis 1.4</a>) and at two years (MD 22.00 μm, 95% CI −45.93 to 89.93; 75 eyes, 1 study, <a href="./references#CD011599-fig-0012" title="">Analysis 1.6</a>). </p> <div class="figure" id="CD011599-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 anti‐VEGF/steroid versus anti‐VEGF, outcome: 1.5 Mean change in central macular thickness at 1 year [μm]." data-id="CD011599-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 anti‐VEGF/steroid versus anti‐VEGF, outcome: 1.5 Mean change in central macular thickness at 1 year [μm]. </p> </div> </div> </div> </section> <section id="CD011599-sec-0074"> <h5 class="title">Adverse effects</h5> <p><a href="#CD011599-tbl-0004">Table 1</a> and <a href="#CD011599-fig-0006">Figure 6</a> summarises the adverse events. There were 92 reported adverse events in eyes receiving intravitreal anti‐VEGF plus steroids compared with 25 adverse events in those receiving intravitreal anti‐VEGF alone (Peto OR 5.66, 95% CI 3.62 to 8.84; 635 eyes; 8 studies). There was less significant intraocular inflammation in the anti‐VEGF/steroid group (Peto OR 0.53, 95% CI 0.05 to 5.08; 635 eyes; 8 studies) however, evidence was of very low‐certainty with 1 event in the anti‐VEGF/steroid group (313 eyes) and 2 events in the anti_VEGF group (322 eyes), Development of cataract was more frequent in eyes receiving anti‐VEGF/steroid compared with IVB (Peto OR 7.49, 95% CI 2.87 to 19.60; 635 eyes; 8 studies) however, evidence was of very low‐certainty, with 18 events in the anti‐VEGF/steroid group (313 eyes) and 1 event in the anti‐VEGF group (322 eyes). Readers should note that cataract development due to intravitreal steroid often occurs after the first year of treatment. There was a substantially greater risk of raised intraocular pressure in eyes receiving anti‐VEGF/steroid compared with anti‐VEGF alone (Peto OR 8.13, 95% CI 4.67 to 14.16; 635 eyes; 8 studies). </p> <div class="figure" id="CD011599-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.7 Adverse events." data-id="CD011599-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.7 Adverse events. </p> </div> </div> </div> <div class="table" id="CD011599-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Significant ocular inflammation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Development of cataract</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Raised intraocular Pressure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Need for glaucoma drainage surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intravitreal anti‐VEGF + steroid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>313</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intravitreal anti‐VEGF</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intravitreal steroid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Macular laser</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> </tbody> </table> </div> <p>One study (<a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a>) with six month follow‐up reported systemic adverse events. The study defined a systemic adverse event as: resulted in death, was life threatening, required hospitalisation or prolongation of an existing hospitalisation, resulted in persistent or significant disability /incapacity; was a congenital anomaly/birth defect. The difference was small, and the confidence intervals corresponded to either fewer or more events occurring. There were more systemic adverse events in the the anti‐VEGF/steroid group (Peto OR 1.32, 95% CI 0.61 to 2.86; 103 eyes; 1 study) with 25 events in the anti‐VEGF plus steroid group (52 eyes) and 21 events in the anti‐VEGF group (51 eyes). </p> </section> <section id="CD011599-sec-0075"> <h5 class="title">Sensitivity analyses</h5> <p>We conducted three sensitivity analyses on the one year data. One analysis excluded <a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> because the study did not report standard deviations for change in visual loss or CMT and had a high risk of selection bias. Another excluded <a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> because the study received funding from industry and also had a high risk of selection bias. The third analysis excluded Soheilian because the study had a high risk of attrition bias.The results were reasonably robust. </p> <p> <div class="table" id="CD011599-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in visual acuity (VA) at one year</p> <p>Mean difference (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in central macular thickness at one year</p> <p>Mean difference (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All 3 studies (<a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a>; <a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a>; <a href="./references#CD011599-bbs2-0011" title="SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187‐95. ">Soheilian 2007</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.29 VA letters (‐6.03 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 μm (‐37.14 to 37.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluding <a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.34 VA letters (‐8.05 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.86 μm (‐35.29 to 57.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluding <a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.11 VA letters (‐7.36 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.05 μm (‐37.89 to 50.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluding <a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.12 VA letters (‐4.96 to 4.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17.77μm (‐65.03 to 29.49)</p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD011599-sec-0076"> <h4 class="title">Intravitreal anti‐VEGF plus steroid compared to macular laser</h4> <section id="CD011599-sec-0077"> <h5 class="title">Visual outcomes</h5> <p>See <a href="./references#CD011599-fig-0015" title="">Analysis 2.1</a>. </p> <p>Eyes that received intravitreal anti‐VEGF plus steroid could, on average, read more letters at one year than those receiving macular laser. The difference was small, and the confidence interval corresponded to either fewer or more letters being read (MD 4.00 VA letters, 95% CI −2.70 to 10.70; 80 eyes; 1 study). The study reported the same pattern at 6 months (MD 6.00 VA letters, 95% CI −0.46 to 12.46; 86 eyes; 1 study) and at two years (MD 3.00 VA letters, 95% CI −4.52 to 10.52; 74 eyes; 1 study). However, participants in this trial received intravitreal anti‐VEGF no more frequently than once every 12 weeks, which is considerably less than more recent trials. </p> </section> <section id="CD011599-sec-0078"> <h5 class="title">Central macular thickness</h5> <p>See <a href="./references#CD011599-fig-0016" title="">Analysis 2.2</a> </p> <p>Eyes that received intravitreal anti‐VEGF plus steroids had more reduction in CMT at one year compared with those receiving macular laser. The difference was small, and the confidence interval corresponded to either increased or decreased CMT (MD 16.00 μm, 95% CI −68.93 to 36.93; 80 eyes; 1 study). </p> </section> <section id="CD011599-sec-0079"> <h5 class="title">Adverse effects</h5> <p>See <a href="./references#CD011599-fig-0017" title="">Analysis 2.3</a> </p> <p>There were 19 adverse events in eyes receiving intravitreal anti‐VEGF plus steroids compared with 1 adverse event in eyes receiving macular laser (Peto OR 9.28, 95% CI 3.50 to 24.60; 100 eyes; 1 study). There was an increased risk of cataract in the anti‐VEGF and steroids group compared with macular laser (Peto OR 4.58, 95% CI 0.99 to 21.10; 100 eyes; 1 study). Risk of raised intraocular pressure was higher in eyes receiving anti‐VEGF plus steroids compared with macular laser (Peto OR 9.49, 95% CI 2.86 to 31.51; 100 eyes; 1 study). </p> </section> </section> <section id="CD011599-sec-0080"> <h4 class="title">Intravitreal anti‐VEGF plus steroid compared with steroid alone</h4> <p>Two studies compared anti‐VEGF/steroid versus IVS (<a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a>; <a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a>) with only one study having 1 year outcomes (<a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a>). The steroid used was intravitreal triamcinolone in both trials. <a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> did not report data on standard deviations for change in BCVA so we have included data on final value in the plot (<a href="./references#CD011599-fig-0018" title="">Analysis 3.1</a>). We judged the certainty of the VA and CMT evidence for this comparison to be low, downgrading for risk of bias in the included trials and imprecision (confidence intervals include both no effect and clinically important differences). </p> <section id="CD011599-sec-0081"> <h5 class="title">Visual outcomes</h5> <p>The mean change in BCVA at one year was 7.5 letters for eyes receiving anti‐VEGF/steroid therapy (36 eyes) compared with 8 letters in the steroid alone arm (37 eyes). The trial authors reported the standard deviation for final value only, not change. The mean difference in final value was 4 letters (95% CI ‐2.6 to 10.6) at six months and 0 letters (95% CI ‐6.1 to 6.1) at one year (<a href="./references#CD011599-fig-0018" title="">Analysis 3.1</a>). </p> </section> <section id="CD011599-sec-0082"> <h5 class="title">Central macular thickness</h5> <p>The mean change in CMT at one year was −199 μm for eyes receiving anti‐VEGF/steroid therapy (36 eyes) compared with −200 μm in the steroid arm (37 eyes). The trial authors reported the standard deviation for final value only, not change. The mean difference in final value was 1.00 µm (95% CI ‐41.92 to 43.92) at six months and ‐9.00 µm (95% CI ‐39.87 to 21.87) at one year (<a href="./references#CD011599-fig-0018" title="">Analysis 3.1</a>). </p> </section> <section id="CD011599-sec-0083"> <h5 class="title">Adverse effects</h5> <p>Raised intraocular pressure occurred at similar rates for eyes receiving intravitreal anti‐VEGF plus steroids versus steroid alone (RR 0.77, 95% CI 0.19 to 3.20, 37 eyes; 1 study). There was a very low‐certainty of evidence with 3 events in the anti‐VEGF/steroid group (36 eyes) and 4 events in the steroid group (37 eyes). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011599-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011599-sec-0084">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011599-sec-0153">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011599-sec-0084"></div> <section id="CD011599-sec-0085"> <h3 class="title" id="CD011599-sec-0085">Summary of main results</h3> <p>There were eight included studies, all at unclear risk of bias in at least one domain. Eyes treated with a combination of inhibitors of vascular endothelial growth factor (VEGF) and steroid therapy achieved similar visual acuity and central macular thickness outcomes as those receiving monotherapy at one year. There was a greater risk of raised intraocular pressure in people receiving intravitreal anti‐VEGF plus steroids compared with anti‐VEGF monotherapy. </p> </section> <section id="CD011599-sec-0086"> <h3 class="title" id="CD011599-sec-0086">Overall completeness and applicability of evidence</h3> <p>The included studies assessed the combination of intravitreal bevacizumab (off‐label) or ranibizumab and either intravitreal triamcinolone (off‐label) or dexamethasone implants for the management of diabetic macular oedema (DMO). There were no published randomised clinical trial results on the combination of licensed VEGF inhibitors with intravitreal steroid agents. Intravitreal bevacizumab was often given at lower frequency in the included studies than is generally recommended. Additionally, in the BEVORDEX randomised clinical trial, intravitreal dexamethasone implants given more frequently, with a minimum interval of 16 weeks, may have better results than the studies included in this review (<a href="./references#CD011599-bbs2-0022" title="GilliesMC , LimLL , CampainA , QuinGJ , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473‐81. ">BEVORDEX 2014</a>, <a href="./references#CD011599-bbs2-0023" title="Fraser‐BellS , LimLL , CampainA , MehtaH , AroneyC , BryantJ , et al. Bevacizumab or dexamethasone implants for DME: 2‐year results (The BEVORDEX Study). Ophthalmology2016;123(6):1399‐01. ">BEVORDEX 2016</a>). Licenced intravitreal anti‐VEGF agents (e.g. aflibercept) may have greater efficacy than the unlicensed intravitreal bevacizumab used in most of the included studies (<a href="./references#CD011599-bbs2-0049" title="VirgiliG , ParravanoM , MenchiniF , EvansJR , GordonI , LucenteforteE . Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis. Cochrane Database of Systematic Reviews2017, Issue 6. [DOI: 10.1002/14651858.CD007419.pub5] ">Virgili 2017</a>). </p> </section> <section id="CD011599-sec-0087"> <h3 class="title" id="CD011599-sec-0087">Quality of the evidence</h3> <p>Many studies did not have sufficient length of follow‐up or were under‐powered to identify significant local (e.g. cataract or glaucoma) or systemic adverse events (e.g. stroke or heart attack). Typically, cataract develops in the second year of treatment. Ideally, trials that involve intravitreal steroid therapy should run for three years to allow sufficient time for cataract to develop, for cataract surgery to be undertaken, and for the study eye to stabilise following surgery. All included studies had unclear risk of bias in one or more domains and three studies (<a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a>; <a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a>; <a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a>) had a high risk of selection bias. Many included studies had a paired design for treatments, which have a theoretical potential to influence outcomes in the fellow eye via systemic absorption. Additionally the disease may not be symmetrical and the paired design may preclude pragmatic trials with economic and quality of life outcomes. Clustering risks could potentially be addressed with statistical methods such as generalised estimated equations, however this was not possible in this review due to absence of available individual patient level data in included studies. The GRADE scores of certainty of evidence from the included studies ranged from very low to moderate. </p> </section> <section id="CD011599-sec-0088"> <h3 class="title" id="CD011599-sec-0088">Potential biases in the review process</h3> <p>We used standard methodological procedures as recommended by Cochrane. As we found fewer than 10 studies, we were unable to use a funnel plot to identify possible publication bias. </p> </section> <section id="CD011599-sec-0089"> <h3 class="title" id="CD011599-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, this is the first systematic review of randomised clinical trials assessing inhibitors of VEGF plus intravitreal steroids for DMO. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011599-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011599-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011599-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011599-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.2 Mean change in visual acuity at 1 year [VA letters]." data-id="CD011599-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.2 Mean change in visual acuity at 1 year [VA letters]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 anti‐VEGF/steroid versus anti‐VEGF, outcome: 1.5 Mean change in central macular thickness at 1 year [μm]." data-id="CD011599-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 anti‐VEGF/steroid versus anti‐VEGF, outcome: 1.5 Mean change in central macular thickness at 1 year [μm]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.7 Adverse events." data-id="CD011599-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.7 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 1 Mean change in visual acuity at 6 months." data-id="CD011599-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 1 Mean change in visual acuity at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 2 Mean change in visual acuity at 1 year." data-id="CD011599-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 2 Mean change in visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 3 Mean change in visual acuity at 2 years." data-id="CD011599-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 3 Mean change in visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 4 Mean change in central macular thickness at 6 months." data-id="CD011599-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 4 Mean change in central macular thickness at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 5 Mean change in central macular thickness at 1 year." data-id="CD011599-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 5 Mean change in central macular thickness at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 6 Mean change in central macular thickness at 2 years." data-id="CD011599-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 6 Mean change in central macular thickness at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 7 Adverse events." data-id="CD011599-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 8 Need for glaucoma drainage surgery." data-id="CD011599-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 8 Need for glaucoma drainage surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 1 Mean change in visual acuity." data-id="CD011599-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 1 Mean change in visual acuity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 2 Mean change in central macular thickness." data-id="CD011599-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 2 Mean change in central macular thickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 3 Adverse events." data-id="CD011599-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 1 Mean change in visual acuity." data-id="CD011599-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 1 Mean change in visual acuity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 2 Mean change in central macular thickness." data-id="CD011599-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 2 Mean change in central macular thickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/urn:x-wiley:14651858:media:CD011599:CD011599-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_t/tCD011599-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 3 Raised intraocular pressure." data-id="CD011599-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 3 Raised intraocular pressure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011599-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Settings</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal anti‐VEGF plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: intravitreal anti‐VEGF </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of eyes<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF alone</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity gain at 1 year ranged from 4.9 to 10.5 letters in the anti‐VEGF alone groups </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read was on average 2.29 fewer in the anti‐VEGF/steroid group (95% CI −6.03 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> <p>(3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in central macular thickness at 1 year ranged from −30 μm to −179 μm in the anti‐VEGF alone groups </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in central macular thickness was on average 0.20 μm greater in the anti‐VEGF/steroid groups (95% CI −37.14 to 37.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> <p>(3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> <p>(0 to 30 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.53 (0.05 to 5.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> <p>(8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 3 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> <p>(9 to 56 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.49 (2.87 to 19.60)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> <p>(8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NB: significant cataract progression may occur in the second year of intravitreal steroid use. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Raised intraocular pressure at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> <p>(27 to 79 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 8.13 (4.67 to 14.16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> <p>(8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant needed glaucoma surgery in the anti‐VEGF/steroid group.<b>This outcome occurred only in 1 study</b>. The threshold for glaucoma drainage surgery was not specified. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>468 per 1000</p> <p>(289 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peto OR 1.32</p> <p>(95% CI 0.61 to 2.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br/> <b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>MD</b> : mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level because of imprecision.<br/> <sup>b</sup>Downgraded one level because of risk of bias, and two levels for imprecision as there were very few events. </p> <p><sup>c</sup>Downgraded one level because of risk of bias </p> <p><sup>d</sup>Downgraded two levels for imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011599-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Setting</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal bevacizumab plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: macular laser </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of eyes<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Macular laser</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity gain at 1 year was 1 letter with a standard deviation of 17 letters in the laser comparator group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read was 4.00 more in the anti‐VEGF/steroid group (95% CI −2.70 to 10.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gain or loss of 10 or more letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in central macular thickness at 1 year was an increase of 6 μm with a standard deviation of 36 microns in the laser comparator group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in central macular thickness was on average 16 μm greater in the anti‐VEGF/steroid group (95% CI −68.93 to 36.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> <p>(20 to 301 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 4.58 (0.99 to 21.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Raised Intraocular Pressure at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> <p>(3 to 31 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 9.49 (2.86 to 31.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was 1 participant who needed glaucoma drainage surgery in the anti‐VEGF/steroid group. Threshold for glaucoma drainage surgery not specified in the included study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br/> <b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>MD</b> : mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level due to imprecision. </p> <p><sup>b</sup>Downgraded one level because of risk of bias and by two levels due to imprecision (only 1 event in the comparator group). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011599-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus intravitreal steroid for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Intravitreal bevacizumab plus intravitreal steroid compared with intravitreal steroid for diabetic macular oedema </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Setting</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal bevacizumab plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: intravitreal steroid (IVS) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of eyes<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainity of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IVS</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity at 1 year was 24.5 letters in the IVS comparator group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read was on average 0 letters higher (i.e same) in the anti‐VEGF/steroid group (95% CI ‐6.1 to 6.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported for change in visual acuity so difference in visual acuity at 1 year reported </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gain or loss of 10 or more letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean central macular thickness was 249 μm in the IVS comparator group at 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean central macular thickness was 9 μm less in the anti‐VEGF/steroid group (‐39.87μm less to 21.87μm more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported for change so difference in final value reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Raised intraocular pressure at 1 year at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> <p>(19 to 301 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.75 (0.16 to 3.55)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br/> <b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>MD</b> : mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level for imprecision. </p> <p><sup>b</sup>Downgraded one level because of risk of bias and by two levels for imprecision (very few events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus intravitreal steroid for diabetic macular oedema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011599-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Significant ocular inflammation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Development of cataract</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Raised intraocular Pressure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Need for glaucoma drainage surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intravitreal anti‐VEGF + steroid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>313</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intravitreal anti‐VEGF</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intravitreal steroid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Macular laser</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0002" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100‐6. ">Lim 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0003" title="MaturiRK , BleauL , SaundersJ , MubasherM , StewartMW . A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina2015;35(8):1604‐14. ">Maturi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0001" title="MaturiRK , GlassmanAR , LiuD , BeckRW , BhavsarAR , BresslerNM , et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmology2018;136(1):29‐38. NCT01945866 . Phase II combination steroid and anti‐VEGF for persistent DME [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). ">DRCRnet U 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0004" title="NCT00737971 . Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). NetoHO , RegatieriCV , NobregaMJ , MuccioliC , CasellaAM , AndradeRE , et al. Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina2017;48(9):734‐40. ">Neto 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0005" title="Riazi‐EsfahaniM , Riazi‐EsfahaniH , AhmadrajiA , KarkhanehR , MahmoudiA , RoohipoorR , et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. International Ophthalmology2017;37:1‐14. ">Riazi‐Esfahani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0006" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483‐9. ShoeibiN , AhmadiehH , EntezariM , YaseriM . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial. Journal of Ophthalmic and Vision Research2013;8(2):99‐106. ">Shoeibi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0007" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314‐21. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142‐50. YaseriM , ZeraatiH , MohammadK , SoheilianM , RamezaniA , EslaniM , et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. Journal of Ophthalmic and Vision Research2014;9(4):453‐60. ">Soheilian 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011599-bbs2-0008" title="SynekS , VeselyP . Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum2011;35(3):841‐5. ">Synek 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011599-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF and steroid versus anti‐VEGF alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean change in visual acuity at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐2.56, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean change in visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.29 [‐6.03, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean change in visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean change in central macular thickness at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.73 [‐40.47, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mean change in central macular thickness at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐37.14, 37.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean change in central macular thickness at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.66 [3.62, 8.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Significant intraocular inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Development of cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.49 [2.87, 19.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Raised intraocular pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.13 [4.67, 14.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Systemic adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.61, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Need for glaucoma drainage surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF and steroid versus anti‐VEGF alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011599-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anti‐VEGF and steroid versus macular laser</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean change in central macular thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Development of cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Raised intraocular pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anti‐VEGF and steroid versus macular laser</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011599-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐VEGF and steroid versus steroid alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean change in central macular thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Raised intraocular pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.11, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐VEGF and steroid versus steroid alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011599.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011599-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011599-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011599-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011599-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011599-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011599\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011599\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011599\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011599\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011599.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011599.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011599.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011599.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011599.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727561168"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011599.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727561172"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011599.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eaf128e70f573',t:'MTc0MDcyNzU2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 